Clinical Scorecard: A Decade of Gadolinium Retention and Deposition: Insights from ESMRMB-GREC on Past and Future Perspectives
At a Glance
Category
Detail
Condition
Gadolinium retention and deposition following use of gadolinium-based contrast agents (GBCA) in MRI
Key Mechanisms
Gadolinium chelation, transmetallation, and elimination; deposition primarily in brain regions such as dentate nucleus and globus pallidus after repeated GBCA exposure
Target Population
Patients undergoing MRI with GBCA, including those with normal and impaired renal function
Care Setting
Radiology and neuroradiology imaging centers performing contrast-enhanced MRI
Key Highlights
Gadolinium deposition in brain first described in 2014, linked to repeated administrations of linear GBCA.
Gadolinium is toxic in unchelated form; chelation stability (thermodynamic and kinetic) influences retention and safety.
Retention occurs mainly in dentate nucleus and globus pallidus, with long-term retention observed preferentially in dentate nucleus.
Guideline-Based Recommendations
Diagnosis
Use unenhanced T1-weighted MRI to detect hyperintensity in dentate nucleus and globus pallidus indicative of gadolinium deposition.
Management
Prefer macrocyclic GBCA over linear agents due to higher stability and lower retention risk.
Consider renal function before GBCA administration; impaired renal clearance increases retention risk.
Monitoring & Follow-up
Monitor patients with repeated GBCA exposure for changes in T1 signal intensity in brain regions.
Assess renal function (eGFR) prior to GBCA use to estimate elimination half-life and retention risk.
Risks
Repeated use of linear GBCA increases risk of gadolinium deposition in brain.
Impaired renal function prolongs GBCA elimination, increasing likelihood of transmetallation and retention.
Potential toxicity from released Gd3+ ions binding to calcium-dependent proteins.
Patient & Prescribing Data
Patients undergoing MRI with GBCA, including those with multiple sclerosis and brain tumors
Linear GBCA associated with higher brain deposition; macrocyclic agents show faster excretion and lower retention; renal impairment prolongs elimination half-life increasing retention risk.
Clinical Best Practices
Use macrocyclic GBCA preferentially to reduce gadolinium retention.
Limit repeated GBCA administrations when possible, especially linear agents.
Evaluate renal function before GBCA administration to minimize retention risk.
Monitor MRI signal changes in dentate nucleus and globus pallidus for evidence of deposition.
Educate patients on potential risks of gadolinium retention, especially with repeated contrast use.
